Comparing the current results to its competitors, Immunitybio Inc reported Revenue increase in the 2 quarter 2026 by 93.91 % year on year. The sales growth was above Immunitybio Inc 's competitors' average revenue growth of 6.9 %, achieved in the same quarter.
July 25, 2025
ImmunityBio Reports Significant Growth in Q2 2025: Revenue Surges by 60% Amid Competitive Landscape CULVER CITY, Calif. ImmunityBio, Inc. (NASDAQ: IBRX), a prominent player in the immunotherapy landscape, has revealed a remarkable financial performance for the fiscal quarter ended June 30, 2025, showcasing a notable revenue increase alongside promising clinical advancements. According to the preliminary financial results, ImmunityBio reported a striking $26.4 million in revenue for Q2 2025, reflecting a significant 60% growth compared to the first quarter of 2025. This comes alongside year-to-date sales of approximately $43 million and a staggering 246% increase in unit sales volume since the company rec...
April 7, 2025
ImmunityBio Advances Immunotherapy Landscape: Key Opinion Leader Meeting and Regulatory Milestones in 2025 Culver City, California - ImmunityBio, Inc. (NASDAQ: IBRX), a pioneering company in the field of immunotherapy, is gearing up for a pivotal moment in its history. The firm has announced that it will host an Investor Day on April 15, 2025, at 10:00 am PDT. This event will highlight the company’s progress in its clinical programs and the much-anticipated launch of ANKTIVA, an innovative immune-oncology treatment designed to combat challenging cancers such as non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC).A Core Component of the Investor Day will be a comprehensive upda...
January 16, 2025
ImmunityBio s Progress in FDA Submissions Amid Market Challenges In a significant development for the oncology sector, ImmunityBio, Inc. (NASDAQ: IBRX) has announced its forward momentum in discussions with the U.S. Food and Drug Administration (FDA) concerning its clinical development activities for non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC). Based in Culver City, California, ImmunityBio, a prominent figure in the field of immunotherapy, is poised to submit a supplemental Biologics License Application (sBLA) in 2025, particularly for NMIBC in BCG-unresponsive papillary disease.This regulatory update follows a productive meeting with the FDA, where ImmunityBio presented...
August 12, 2024
CULVER CITY, Calif. ImmunityBio, Inc. (NASDAQ: IBRX) has made a significant leap in the accessibility of its cancer treatment, ANKTIVA (nogapendekin alfa inbakicept-pmln), securing coverage from more than a dozen insurance plans. This move represents over 100 million lives covered just months following the drug s FDA approval, marking an important milestone for patients seeking alternative therapies for their conditions.The company announced this development as it continues to push for broad market access for ANKTIVA, focusing on both commercial and government insurance programs. This strategy is pivotal for ensuring that patients diagnosed with bladder cancer have the necessary support to receive the inn...
May 18, 2024
CULVER CITY, Calif. ImmunityBio, Inc. (NASDAQ: IBRX) has made significant strides in the arena of bladder cancer treatment. Highlighting these breakthroughs, a series of three enlightening podcasts were recently published on UroToday. These podcasts centered around an in-depth discussion with Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific at ImmunityBio, and Dr. Ashish Kamat, an esteemed urologist. The focus The FDA s recent approval of ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) in conjunction with Bacillus Calmette-Guerin (BCG) for treating non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), as well as other promising advancements in bladder cancer res...
May 7, 2024
U.S.-based immunotherapy company, ImmunityBio Inc. (NASDAQ: IBRX), recently confirmed that it has successfully completed manufacturing the Drug Substance (DS), a key component required for creating its biotherapeutic drug, ANKTIVA (nogapendekin alfa inbakicept-pmln). With this critical process accomplished, an estimated 170,000 doses of 400mcg ANKTIVA are deemed ready to be rolled out post packaging and vial filling - a procedure commonly referred to as fill finish.This latest developmental stride follows the progressive launch of ANKTIVA a clinical-stage immunotherapy developed with the potential to stimulate natural killer cells and boost patients immune responses. The successful production of this Drug...
April 30, 2024
In a ground-breaking announcement that marked a new chapter in cancer therapy, ImmunityBio unveiled news of the FDA s recent approval of ANKTIVA (nogapendekin alfa inbakicept-pmln). The historic announcement was made by the Executive Chairman, Dr. Patrick Soon-Shiong, during a fireside chat at the Annual Conference of the American Urological Association.Held in Culver City, California, the American Urological Association s annual conference was a fitting idyllic backdrop for the groundbreaking revelation. As an established field leader, Dr. Soon-Shiong s fireside discussion held a particular gravitas that had the industry s reputed professionals listening eagerly. A next-generation immunotherapy company, Imm...
April 25, 2024
In a recent announcement, ImmunityBio, a leading immunotherapy company, shared positive overall survival outcomes from the QUILT 3.055 study. The study evaluated the effectiveness of ANKTIVA (N-803) in combination with checkpoint inhibitors for patients with non-small cell lung cancer (NSCLC) who had experienced disease progression after prior checkpoint inhibitor therapy and standard-of-care chemotherapy.ANKTIVA and its Unique Mechanism of Action:ANKTIVA is a novel immunotherapy agent that harnesses the power of natural killer (NK) cells to fight cancer. These NK cells are a crucial part of the body s immune system, responsible for detecting and eliminating abnormal cells, including tumor cells. Through its...
March 5, 2024
In a groundbreaking pilot study, ImmunityBio has announced significant findings indicating the potential of their immunotherapy drug, N-803, combined with natural killer (NK) cells in reducing the viral load in individuals living with HIV. The encouraging results were published in The Journal of Infectious Diseases, shedding new light on the pursuit of an effective HIV cure. The study conducted by researchers at the University of Minnesota Medical School showcased how N-803 boosts NK cell activity when infused into HIV-positive individuals.Study Details and Findings:The Phase 1 pilot study enrolled six HIV-positive individuals who received infusions of healthy NK cells obtained from close relatives along wit...
Alector Inc's business model focuses on developing novel therapeutics for neurodegenerative diseases using its proprietary platform and partnering with pharmaceutical companies for clinical trials and commercialization.
Dyadic International Inc's business model revolves around developing and licensing proprietary microbial strains and technologies for use in the biopharmaceutical, biofuels, and industrial enzyme industries.
Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.
Fate Therapeutics Inc's business model revolves around the development and commercialization of innovative cell-based therapies to treat various diseases.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Sources:
Immunitybio inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Immunitybio inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
